RTW Investments LP Has $56.51 Million Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

RTW Investments LP increased its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 10.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,123,525 shares of the company’s stock after buying an additional 471,240 shares during the quarter. RTW Investments LP owned about 0.10% of Stoke Therapeutics worth $56,512,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of STOK. KLP Kapitalforvaltning AS acquired a new stake in shares of Stoke Therapeutics in the 4th quarter valued at $63,000. Teacher Retirement System of Texas bought a new position in Stoke Therapeutics during the 4th quarter worth $113,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Stoke Therapeutics in the 4th quarter worth about $124,000. Tower Research Capital LLC TRC raised its position in shares of Stoke Therapeutics by 70.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock worth $132,000 after acquiring an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. bought a new position in shares of Stoke Therapeutics in the 4th quarter worth about $133,000.

Stoke Therapeutics Price Performance

NASDAQ:STOK opened at $9.63 on Friday. The company has a market cap of $525.77 million, a P/E ratio of -4.59 and a beta of 1.20. The stock’s fifty day moving average price is $8.12 and its two-hundred day moving average price is $9.99. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.38. The firm had revenue of $22.61 million for the quarter, compared to analysts’ expectations of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on STOK shares. Cantor Fitzgerald upgraded Stoke Therapeutics to a “strong-buy” rating in a research note on Wednesday. Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Chardan Capital restated a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Finally, HC Wainwright lowered their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $23.20.

Insider Transactions at Stoke Therapeutics

In other news, insider Barry Ticho sold 3,884 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares of the company’s stock, valued at approximately $554,550.54. This trade represents a 5.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the transaction, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. This trade represents a 6.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is currently owned by company insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.